HLA
IDYA icon

Hamilton Lane Advisors’s IDEAYA Biosciences IDYA Stock Holding History

Hamilton Lane Advisors’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,692
Closed -$640K – 76
2020
Q4 		$640K Buy
+45,692
New +$619K 0.24% 42

Other funds holding IDYA

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hamilton Lane Advisors's IDYA Position: Q1 2021 in Review

Hamilton Lane Advisors sold out of IDEAYA Biosciences (IDYA) in Q1 2021, closing a stake of 45,692 shares — an estimated $640K sold.

Hamilton Lane Advisors first reported a position in IDYA in Q4 2020 and held it in 1 quarter. The position peaked at $640K in Q4 2020. 89 funds tracked by Wall St. Rank hold IDYA as of Q1 2021.

  • Hamilton Lane Advisors reported no remaining IDEAYA Biosciences position as of Q1 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 45,692 IDEAYA Biosciences shares in Q1 2021, an estimated $640K.
  • Hamilton Lane Advisors first reported a position in IDEAYA Biosciences in Q4 2020 and held it in 1 quarter.
  • Hamilton Lane Advisors's IDEAYA Biosciences position peaked at $640K in Q4 2020.
  • 89 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2021.

Based on Hamilton Lane Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.